ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2002

Do SMS and Email Reminders Increase the Rate of Seasonal Influenza Vaccination in RA Patients Treated with Biologics: A Nested Randomized Controlled Trial Within the ART Registry?
Abstract Number: 0122

Documentation of Social Determinants of Health Among Individuals with Systemic Rheumatic and Musculoskeletal Diseases
Abstract Number: 0110

Does Access Reduce Excess Use? Lupus Outcomes in Two Distinct Socioeconomic Groups Seen by University Rheumatologists
Abstract Number: 2045

Does Ancestry Influence Primary Sjögren’s Syndrome Phenotype or Severity?
Abstract Number: 2077

Does Early Complete Remission Preclude Adverse Outcomes in Lupus Nephritis?
Abstract Number: 1905

Does Exercise Before Surgery Predict Trajectories of Physical Activity After Knee Replacement?
Abstract Number: 0087

Does Limited English Proficiency Lead to Additional Health Inequity in Medically Vulnerable Populations in Outpatient Rheumatology?
Abstract Number: 1003

Does LLDAS Definition Match the Rheumatologist Opinion? The First Visit Evaluation of a Longinudital Spanish Multicenter Study to Assess Reasons of Disagreement
Abstract Number: 1903

Does Pain Sensitization by Pressure Pain Thresholds and Temporal Summation Predict Persistent Pain in Persons with Hand OA?
Abstract Number: 2102

Does Remission According Definition of Remission in SLE (DORIS) 2021 Match the Treating Rheumatologist Judgment? Analysis at Recruitment of a Prospective Study of 500 SLE Patients from a Spanish Multicenter Cohort
Abstract Number: 1264

Does Vein Wall Thickness Have Prognostic Value in Behcet’s Disease? A Prospective Follow up Study
Abstract Number: 2109

Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Abstract Number: 0312

Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis
Abstract Number: 1169

Downregulated Fli1 in Systemic Sclerosis Myeloid Cells Contributes to Enhanced Transendothelial Migration
Abstract Number: 0499

Drivers of Heterogeneity in Synovial Fibroblasts in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].